Securus Medical, which is developing a real-time thermal mapping system to measure core body temperature, raised $10 million in a Series C round led by Boston Scientific. The funding will go toward further product development and clinical investigation of its device.
The device, the infrared thermographic system (IRTS), recently received FDA clearance, the company said in a statement. It is an intrabody thermal measurement device intended for the continuous monitoring of esophageal temperature.
In addition to Boston Scientific, existing investors RiverVest Venture Partners, 3X5 Special Opportunity Fund and the University of Michigan’s Investment in New Technology Startups (MINTS) program also participated in the round.
"This financing accelerates Securus Medical Group's technology development, and importantly it enables further validation of the Company's core technology which holds great potential to change the standard of care for esophageal temperature monitoring,” said Karen Spilizewski, RiverVest Venture Partners vice president and a Securus board member, in the statement.
The company previously raised $6.5 million in a 2013 Series B round.